ArticleFrontiers in oncology2021

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.

Uros Markovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.